2008
DOI: 10.1111/j.1528-1167.2008.01624.x
|View full text |Cite
|
Sign up to set email alerts
|

Anticonvulsant profile and teratogenicity of 3,3‐dimethylbutanoylurea: A potential for a second generation drug to valproic acid

Abstract: SUMMARYPurpose: The purpose of this study was to evaluate the anticonvulsant activity and teratogenic potential of branched aliphatic acylureas represented by isovaleroylurea (IVU), pivaloylurea (PVU) and 3,3-dimethylbutanoylurea (DBU), as potential secondgeneration drugs to valproic acid (VPA). Methods: The anticonvulsant activity of IVU, PVU, and DBU was determined in mice and rats utilizing the maximal electroshock seizure (MES) and the pentylenetetrazole (scMet) tests. The ability of DBU to block electrica… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
15
0
1

Year Published

2009
2009
2021
2021

Publication Types

Select...
7

Relationship

3
4

Authors

Journals

citations
Cited by 17 publications
(16 citation statements)
references
References 46 publications
0
15
0
1
Order By: Relevance
“…Bialer and colleagues utilized pharmaco- and toxico-kinetic considerations in designing various derivatives of VPA that are more potent as anticonvulsants and have the potential to be non-teratogenic and non-hepatotoxic [Bialer, 1999]. In a comparative teratogenicity studies several VPA analogs and stereoisomers were tested on mice showing variable teratogenic potential dependent on the chemical structure [Kaufmann et al, 2010; Pessah et al, 2010; Shimshoni et al, 2008; Sobol et al, 2006]. A number of hypotheses have been set forward in an attempt to elucidate the mechanism by which VPA disrupts embryonic development.…”
Section: Antiepileptic Drugsmentioning
confidence: 99%
“…Bialer and colleagues utilized pharmaco- and toxico-kinetic considerations in designing various derivatives of VPA that are more potent as anticonvulsants and have the potential to be non-teratogenic and non-hepatotoxic [Bialer, 1999]. In a comparative teratogenicity studies several VPA analogs and stereoisomers were tested on mice showing variable teratogenic potential dependent on the chemical structure [Kaufmann et al, 2010; Pessah et al, 2010; Shimshoni et al, 2008; Sobol et al, 2006]. A number of hypotheses have been set forward in an attempt to elucidate the mechanism by which VPA disrupts embryonic development.…”
Section: Antiepileptic Drugsmentioning
confidence: 99%
“…1b). We, therefore, suggest that the large variations in the seizure-inducing and lethal doses of picrotoxin reported in the literature (Cymerblit-Sabba and Schiller 2010; Klaassen et al 2006;Makinson et al 2014;Shimshoni et al 2008) are caused by variations in the time different laboratories take from preparing picrotoxin solutions to dosing animals. We recommend that picrotoxinin solutions always be freshly prepared immediately before dosing animals.…”
Section: Discussionmentioning
confidence: 86%
“…Another fact that puzzled us is that the reported seizure-inducing and lethal doses for picrotoxin, roughly 50% of which is the active picrotoxinin, vary so widely in the literature. Picrotoxin doses administered intraperitoneally to induced seizures in animal models range from as low as 0.1 mg/kg to doses as high as 30 mg/kg in mice or rats (Cymerblit-Sabba and Schiller 2010; Klaassen et al 2006), but average between 3-10 mg/kg (Makinson et al 2014;Shimshoni et al 2008). The reported LD 50 s vary from 3 to 50 mg/kg (Pericic and Bujas 1997;Pericic et al 2000;Szabo et al 1984).…”
Section: Introductionmentioning
confidence: 99%
“…VCD has 3–10 times more potent anticonvulsant activity than VPA in different animal models (Bialer and White, 2010; Bialer and Yagen, 2007; Isoherranen et al, 2003; Shekh-Ahmad et al, 2013; Shimshoni et al, 2008; Wlodarczyk et al, 2015). Racemic-VCD also has shown efficacy in BD mania in a double-blind controlled Phase IIa clinical trial as add-on to risperidone (Bersudsky et al, 2010), and in a Phase IIb study as monotherapy on patients who remained on the drug (Bialer et al, 2015).…”
Section: Introductionmentioning
confidence: 99%